ArticleRheumatology (Oxford, England)2016
Predictors of relapse and treatment outcomes in biopsy-proven giant cell arteritis: a retrospective cohort study.
Article in Rheumatology (Oxford, England), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
67 citing papers in PubMed, 5 syntheses or guidelines pooled it, 167 citations in OpenAlex.
- Mortality risk and causes of death in exogenous Cushing's syndrome: a systematic review and meta-analysis.The Journal of clinical endocrinology and metabolism · 2026Pooled it
- Evidence on treat to target strategies in polymyalgia rheumatica and giant cell arteritis: a systematic literature review.Rheumatology (Oxford, England) · 2024Pooled it
- Pooled it
- Giant cell arteritis associated with inflammatory bowel disease: a case-series and review of the literature.Rheumatology international · 2021Pooled it
- Pooled it
- New-onset versus relapsing giant cell arteritis treated with tocilizumab: 3-year results from a randomized controlled trial and extension.Rheumatology (Oxford, England) · 2022Trial
- Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial.Annals of the rheumatic diseases · 2022Trial
- Treatment failure in giant cell arteritis.Annals of the rheumatic diseases · 2021Trial
- Real-World Steroid Burden, Treatment Patterns, and Rheumatologists' Perceptions on Advanced Therapy in Giant Cell Arteritis.Rheumatology and therapy · 2026Article
- Treatment strategies in giant cell arteritis and polymyalgia rheumatica: beyond glucocorticoids.Nature reviews. Rheumatology · 2026Review
- Janus Kinase inhibitors in the treatment of large vessel vasculitis: a systematic review and meta-analysis.Open medicine (Warsaw, Poland) · 2026Article
- Scoping review of clinical, laboratory, histopathological and imaging predictors of relapse in adults with biopsy- or temporal artery ultrasound-confirmed giant cell arteritis on standard therapy with glucocorticoids alone or in combination with biologics.Rheumatology advances in practice · 2026Review
- Longitudinal changes on cranial magnetic resonance imaging in relapsing giant cell arteritis.Seminars in arthritis and rheumatism · 2025Article
- Biopsy-proven PACNS: results from the large, multicentre cohort of cerebral vasculitis patients.Journal of neurology, neurosurgery, and psychiatry · 2025Article
- Repeated Cranial and Large-Vessel Positron Emission Tomography/Computed Tomography Scans and the Association With Structural Aortic Disease in Giant Cell Arteritis: A Five-Year Observational Study.ACR open rheumatology · 2025Article
- Treatment and risk of relapse in GCA in Western Norway 2013-2020: a retrospective cohort study.Rheumatology advances in practice · 2025Article
- Effectiveness of a 26-week glucocorticoid taper in giant cell arteritis treated with tocilizumab in real-world clinical practice: a single-centre cohort study.Rheumatology advances in practice · 2025Article
- Does tocilizumab eliminate inflammation in GCA? A cohort study on repeated temporal artery biopsies.RMD open · 2024Article
- Giant cell arteritis in South Korea.Journal of rheumatic diseases · 2024Article
- Clinical characteristics and courses of Korean patients with giant cell arteritis: a multi-center retrospective study.Journal of rheumatic diseases · 2024Article
7 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
Abstract
objectiveTo evaluate characteristics of relapse, relapse rates, treatment and outcomes among patients with biopsy-proven GCA in a large, single-institution cohort.
methodsWe conducted a retrospective review of all patients with biopsy-proven GCA from 1998 to 2013. Demographic, clinical, laboratory and treatment data at presentation and during follow-up were collected. Comparisons by relapse rate were performed using chi-square tests. Prednisone discontinuation by initial oral dose ≤40 and >40 mg/day was compared using Cox models.
resultsThe cohort included 286 patients [74% female, mean age at diagnosis 75.0 years (s.d. 7.6), median follow-up 5.1 years). During follow-up, 73 patients did not relapse, 80 patients had one relapse and 133 had two or more relapses. The first relapse occurred during the first year in 50% of patients, by 2 years in 68% and by 5 years in 79%. More patients with established hypertension (P = 0.007) and diabetes (P = 0.039) at GCA diagnosis were in the high relapse rate group ( ≥ 0.5 relapses/year) and more females were in the low or high relapse groups than in the no relapse group (P = 0.034). Patients receiving an initial oral prednisone dose >40 mg/day were able to reach a dose of <5 mg/day [hazard ratio (HR) 1.46 (95% CI 1.09, 1.96)] and discontinue prednisone [HR 1.56 (95% CI 1.09, 2.23)] sooner than patients receiving ≤40 mg/day without an increase in observed glucocorticoid-associated adverse events.
conclusionFemales and patients with hypertension or diabetes at GCA diagnosis have more relapses during follow-up. Patients treated with an initial oral prednisone dose >40 mg/day achieved earlier prednisone discontinuation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.